Affordable Access

The safety of biologic agents in the treatment of inflammatory bowel disease.

Authors
Type
Published Article
Journal
Minnesota medicine
Publication Date
Volume
91
Issue
6
Pages
42–45
Identifiers
PMID: 18616021
Source
Medline

Abstract

In the last decade, a new class of drugs referred to as biologics has been used successfully for treating patients with inflammatory bowel disease (IBD). Drugs such as infliximab, adalimumab, and certolizumab have been important treatment advancements because they allow the direct targeting of the inflammatory cytokine tumor necrosis factor alpha (TNF-alpha), which is elevated in the blood, stool, and tissue of patients with IBD. Evidence about the benefits of these drugs is accumulating. However, they are not risk-free, and evidence of their risks--primarily infection and malignancy--is also mounting. This article reviews that body of research and offers advice for physicians who must counsel patients about whether the benefits of these treatments outweigh the risks.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments